These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 34398474)

  • 1. Plasma total tau predicts executive dysfunction in Parkinson's disease.
    Lin WT; Shaw JS; Cheng FY; Chen PH
    Acta Neurol Scand; 2022 Jan; 145(1):30-37. PubMed ID: 34398474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease.
    Stav AL; Aarsland D; Johansen KK; Hessen E; Auning E; Fladby T
    Parkinsonism Relat Disord; 2015 Jul; 21(7):758-64. PubMed ID: 25971633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma tau protein and Aβ42 level as markers of cognitive impairment in patients with Parkinson's disease.
    Chojdak-Łukasiewicz J; Małodobra-Mazur M; Zimny A; Noga L; Paradowski B
    Adv Clin Exp Med; 2020 Jan; 29(1):115-121. PubMed ID: 31990459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease.
    Skogseth RE; Bronnick K; Pereira JB; Mollenhauer B; Weintraub D; Fladby T; Aarsland D
    J Parkinsons Dis; 2015; 5(4):783-92. PubMed ID: 26599300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diffusion and structural MRI as potential biomarkers in people with Parkinson's disease and cognitive impairment.
    Huang CC; Chen PH; Tsai CC; Chiang HF; Hsieh CC; Chen TL; Liao WH; Chen YL; Wang JJ
    Eur Radiol; 2024 Jan; 34(1):126-135. PubMed ID: 37572194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma α-synuclein and phosphorylated tau 181 as a diagnostic biomarker panel for de novo Parkinson's disease.
    Ren J; Pan C; Wang Y; Xue C; Lin H; Xu J; Wang H; Zhang W; Xu P; Chen Y; Liu W
    J Neurochem; 2022 Jun; 161(6):506-515. PubMed ID: 35234288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma extracellular vesicles tau and β-amyloid as biomarkers of cognitive dysfunction of Parkinson's disease.
    Chung CC; Chan L; Chen JH; Bamodu OA; Chiu HW; Hong CT
    FASEB J; 2021 Oct; 35(10):e21895. PubMed ID: 34478572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.
    Kang JH; Mollenhauer B; Coffey CS; Toledo JB; Weintraub D; Galasko DR; Irwin DJ; Van Deerlin V; Chen-Plotkin AS; Caspell-Garcia C; Waligórska T; Taylor P; Shah N; Pan S; Zero P; Frasier M; Marek K; Kieburtz K; Jennings D; Tanner CM; Simuni T; Singleton A; Toga AW; Chowdhury S; Trojanowski JQ; Shaw LM;
    Acta Neuropathol; 2016 Jun; 131(6):935-49. PubMed ID: 27021906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal striatal dopamine transporter binding and cerebrospinal fluid alpha-synuclein, amyloid beta, total tau, and phosphorylated tau in Parkinson's disease.
    Nabizadeh F; Pirahesh K; Ramezannezhad E
    Neurol Sci; 2023 Feb; 44(2):573-585. PubMed ID: 36227385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High discriminatory ability of peripheral and CFSF biomarkers in Lewy body diseases.
    Bougea A; Stefanis L; Emmanouilidou E; Vekrelis K; Kapaki E
    J Neural Transm (Vienna); 2020 Mar; 127(3):311-322. PubMed ID: 31912280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A task-specific cognitive domain decline is correlated with plasma and neuroimaging markers in patients with Parkinson's disease.
    Li CH; Chen TF; Peng PL; Lin CH
    J Neurol; 2022 Dec; 269(12):6530-6543. PubMed ID: 35965282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extracellular vesicle biomarkers for cognitive impairment in Parkinson's disease.
    Blommer J; Pitcher T; Mustapic M; Eren E; Yao PJ; Vreones MP; Pucha KA; Dalrymple-Alford J; Shoorangiz R; Meissner WG; Anderson T; Kapogiannis D
    Brain; 2023 Jan; 146(1):195-208. PubMed ID: 35833836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution and Predictive Role of Plasma Alzheimer's Disease-related Pathological Biomarkers in Parkinson's Disease.
    Lin J; Ou R; Li C; Hou Y; Zhang L; Wei Q; Liu K; Jiang Q; Yang T; Xiao Y; Pang D; Zhao B; Chen X; Yang J; Shang H
    J Gerontol A Biol Sci Med Sci; 2023 Dec; 78(12):2203-2213. PubMed ID: 37560912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma α-synuclein predicts cognitive decline in Parkinson's disease.
    Lin CH; Yang SY; Horng HE; Yang CC; Chieh JJ; Chen HH; Liu BH; Chiu MJ
    J Neurol Neurosurg Psychiatry; 2017 Oct; 88(10):818-824. PubMed ID: 28550072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CSF Biomarkers Reflecting Protein Pathology and Axonal Degeneration Are Associated with Memory, Attentional, and Executive Functioning in Early-Stage Parkinson's Disease.
    Oosterveld LP; Kuiper TI; Majbour NK; Verberk IMW; van Dijk KD; Twisk JWR; El-Agnaf OM; Teunissen CE; Weinstein HC; Klein M; Berendse HW; van de Berg WDJ
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33198266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lower Plasma α-Synuclein Levels are Associated with Cognitive Impairment in Parkinson's Disease.
    Song Z; Shen J; Liu Y; Du X; Wu Y; Liu X; Zhang J
    Clin Lab; 2021 May; 67(5):. PubMed ID: 33978361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features.
    Goldman JG; Andrews H; Amara A; Naito A; Alcalay RN; Shaw LM; Taylor P; Xie T; Tuite P; Henchcliffe C; Hogarth P; Frank S; Saint-Hilaire MH; Frasier M; Arnedo V; Reimer AN; Sutherland M; Swanson-Fischer C; Gwinn K; ; Kang UJ
    Mov Disord; 2018 Feb; 33(2):282-288. PubMed ID: 29205509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study.
    Alves G; Brønnick K; Aarsland D; Blennow K; Zetterberg H; Ballard C; Kurz MW; Andreasson U; Tysnes OB; Larsen JP; Mulugeta E
    J Neurol Neurosurg Psychiatry; 2010 Oct; 81(10):1080-6. PubMed ID: 20547614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.
    Kang JH; Irwin DJ; Chen-Plotkin AS; Siderowf A; Caspell C; Coffey CS; Waligórska T; Taylor P; Pan S; Frasier M; Marek K; Kieburtz K; Jennings D; Simuni T; Tanner CM; Singleton A; Toga AW; Chowdhury S; Mollenhauer B; Trojanowski JQ; Shaw LM;
    JAMA Neurol; 2013 Oct; 70(10):1277-87. PubMed ID: 23979011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid levels of alpha-synuclein, amyloid β, tau, phosphorylated tau, and neuron-specific enolase in patients with Parkinson's disease, dementia with Lewy bodies or other neurological disorders: Their relationships with cognition and nuclear medicine imaging findings.
    Katayama T; Sawada J; Kikuchi-Takeguchi S; Kano K; Takahashi K; Saito T; Okizaki A; Hasebe N
    Neurosci Lett; 2020 Jan; 715():134564. PubMed ID: 31733322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.